BILL & MELINDA GATES FOUNDATION (BMGF) RESPONSE TO COVID-19 FOCUSES ON FOUR GOALS
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
BILL & MELINDA GATES FOUNDATION (BMGF)
RESPONSE TO COVID-19 FOCUSES ON FOUR GOALS
Starting in January 2020, our foundation laid out a multi-pronged strategy for response.
© Bill & Melinda Gates Foundation | 1
COVID19 VACCINES HAD AN ACCELERATED DISCOVERY PHASE
Immunogen
selection
Vaccine
dose,
2017 3 months regimen
SARS2 Immunogen Stabilized S2P Preclinical models Phase 1: optimization
Prototype mRNA Vx
Crystal design immunogen e.g. NHP or hamsters Healthy
pathogen
structure Volunteers
(MERS,SARS-1)
© Bill & Melinda Gates Foundation | 2
INEQUITY IN VACCINES ACCESS IS A GLOBAL THREAT
In High Income Countries: In Low and Middle Income
Countries:
• Vaccines will be available in
early 2021 • Vaccine will not become
available until late 2021 or
• Healthcare works will be
2022
protected
• Only 20% of the population
• The vulnerable will be
will be covered
covered and deaths will fall
• Poor coverage of healthcare
• Sufficient doses will be
workers will result in health
available to cover 3-4x
system collapse
population
• Ongoing community
• Boosting will be feasible if
transmission will be an
needed
issue
• Transmission will be
• Sustainable response will
controlled
be problematic
• Community transmission
will continue to seed local
and global outbreak
© Bill & Melinda Gates Foundation | 3SIGNIFICANT RISKS REMAIN TO DELIVERING VACCINES
TO LMICS
Key risks:
1. Gap to Target LMIC Volume: Large volumes beyond the 2021 target 2 billion doses will be required
to immunize high risk populations in LMIC.
2. Tech transfer: Large volume of successful tech transfers is required to meet promised volumes of
wave 1 vaccines on projected timelines
3. Regulatory: Potential regulatory hurdles remain prior to licensure. Long-term safety of wave 1
vaccines using unprecedented approaches is unknown. The path for follow-on vaccines is not
straightforward.
4. Pricing: Relative volume of vaccine available at LMIC affordable prices still unknown
5. Sustainability: Control of transmission may require much higher coverage. Durability is unknown and
boosting may be required
4WAVE 2 VACCINE PORTFOLIO IS DIFFERENTIATED FROM WAVE 1 AND
FOCUSES ON VACCINES THAT ARE MORE SUITABLE FOR LMICS
Wave 2 Location Manufacturi Antigen Current Different Likely lower Possible Refrigerator Precedent in No Tech High
Vaccines ng platform phase antigen 1 COGs single stable pregnant Transfer volum e3
vs w ave 1 dose w omen2
SK South Protein RBD-NP Late
Korea (CHO + preclinical x x x x x +++
E.coli)
SI UK/India Protein RBD-VLP Phase 1
(Pichia) x x x x x +++
Walvax China Protein Spike -deltaTM Late
(CHO) preclinical x x x +++
BioE India Protein RBD Phase 1
(Pichia) x x x x x +++
Zhifei/IMCAS China Protein RBD-dimer Phase 2
(CHO) x x x x x ++
Icosavax USA Protein RBD-NP Late
(CHO + preclinical x x x x ++
E.coli)
Gritstone USA Viral vector Spike variants Early + T cells
+T cell preclinical x ++
epitopes
AAVCOVID USA DNA S-protein Late + to +++
preclinical ? x ? (? dose)
PATH-ISMSS Global Inactivate Hexapro spike Late
viral (eggs) preclinical x x x x x ++
Imperial UK saRNA Stabilized Phase 1
++
spike protein
1 Different antigen: all wave 1 vaccines are full length spike; 2 Adjuvant dependent; 3 Volume: Annual DS by end 2021 (Company estimate / BMGF estimate)
© Bill & Melinda Gates Foundation | 5You can also read
